AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22471971 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochures, web-based advice, exercise suggestions)
Number of subjects: 0
Study 20090338 — intervention group
Group type: COMPARATOR
Intervention: 100 U BT injection (Group A)
Number of subjects: 90
Study 20090338 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation (Group B)
Number of subjects: 90
Study 20090338 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation plus 100 U BT injection (Group C)
Number of subjects: 90
Study 17350629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg daily of synthetic conjugated estrogens A
Number of subjects: 0
Study 17350629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15188350 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg daily subcutaneous injection)
Number of subjects: 1414
Study 15188350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study 15188350 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 1414
Study 15188350 — intervention group
Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 1414
Study 11467090 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50
Study 11467090 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 50
Study 9669057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg once daily
Number of subjects: 189
Study 9669057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg once daily
Number of subjects: 189
Study 9669057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 7833222 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (Pt, 0.67 mg)
Number of subjects: 12
Study 7833222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 17171860 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular heart disease (group V)
Number of subjects: 13
Study 17171860 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (group C)
Number of subjects: 13
Study 17171860 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 13
Study 30106528 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step 0.454% SnF₂ dentifrice then 3% H₂O₂ whitening gel sequence
Number of subjects: 61
Study 30106528 — intervention group
Group type: COMPARATOR
Intervention: Regular 0.76% NaMFP dentifrice control
Number of subjects: 61
Study 28258664 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group E)
Number of subjects: 96
Study 28258664 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (group P)
Number of subjects: 96
Study 28258664 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 96
Study 28258664 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 96
Study 25486333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naringin (1050 mg)
Number of subjects: 10
Study 25486333 — intervention group
Group type: COMPARATOR
Intervention: Control (100 mg talinolol only)
Number of subjects: 10
Study 23874093 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE for COPD manual
Number of subjects: 37
Study 21189384 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI plus systemic therapy with bevacizumab (Bev)
Number of subjects: 73
Study 21189384 — intervention group
Group type: COMPARATOR
Intervention: HAI plus systemic therapy without bevacizumab (no Bev)
Number of subjects: 73
Study 18285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast intensity-modulated radiation therapy (IMRT)
Number of subjects: 331
Study 18285602 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy using wedges
Number of subjects: 331
Study 18285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist desquamation presence
Number of subjects: 331
Study 16571277 — intervention group
Group type: EXPERIMENTAL
Intervention: SSLA 200 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group A)
Number of subjects: 480
Study 16571277 — intervention group
Group type: EXPERIMENTAL
Intervention: SSLA 400 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group B)
Number of subjects: 480
Study 16571277 — intervention group
Group type: COMPARATOR
Intervention: DSI 20 ml daily (control group)
Number of subjects: 480
Study 15072499 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer approaches to the management of penile cancer including laser, photodynamic therapy, neoadjuvant therapy, and sentinel node mapping by lympho‐gamma‐scintigraphy.
Number of subjects: 0
Study 15072499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lymphadenectomy techniques such as the use of ligasure, modified dissection, saphenous vein sparing, and lymphoscintigraphy.
Number of subjects: 0
Study 10949722 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and non-steroidal anti-inflammatory drugs as needed
Number of subjects: 139
Study 8766611 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group I)
Number of subjects: 22
Study 8766611 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition via jejunostomy (Group II)
Number of subjects: 22
Study 8766611 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 22
Study 1557241 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 25
Study 1557241 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 25
Study 3893387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 93
Study 3893387 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol-gentamicin
Number of subjects: 93
Study 30979026 — intervention group
Group type: EXPERIMENTAL
Intervention: Including all affective attitude items
Number of subjects: 1623
Study 30979026 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective attitude items replaced
Number of subjects: 1623
Study 30979026 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively-worded affective attitude items replaced
Number of subjects: 1623
Study 30979026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of data from both studies
Number of subjects: 1623
Study 30979026 — intervention group
Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 1623
Study 30026931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower (ACT) telemedicine-based decision support system
Number of subjects: 12000
Study 30026931 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard intraoperative care
Number of subjects: 12000
Study 30026931 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based decision support system (Anesthesiology Control Tower)
Number of subjects: 12000
Study 27619174 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with daily text-messaging (WB + M)
Number of subjects: 154
Study 27619174 — intervention group
Group type: COMPARATOR
Intervention: Web-based nutrition intervention only (WBO)
Number of subjects: 154
Study 27619174 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 154
Study 25345739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40-120 mg/day)
Number of subjects: 74
Study 25345739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 22081056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered symptom management intervention
Number of subjects: 169
Study 22081056 — intervention group
Group type: COMPARATOR
Intervention: Coach-led intervention
Number of subjects: 169
Study 19421788 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 50
Study 19421788 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (750 mg PO every 6 hours)
Number of subjects: 50
Study 19421788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17541072 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS)
Number of subjects: 24
Study 17541072 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study 15385340 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NIPSV)
Number of subjects: 150
Study 15385340 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 150
Study 15385340 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 150
Study 15385340 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 150
Study 11263636 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 968
Study 11263636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 11263636 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 968
Study 9696467 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of morphine (group A)
Number of subjects: 44
Study 9696467 — intervention group
Group type: COMPARATOR
Intervention: Saline (group B)
Number of subjects: 44
Study 7853327 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 28
Study 7853327 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 28
Study 2756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 44
Study 2756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric sweet drinks (sucrose)
Number of subjects: 44
Study 2756027 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 44
Study 2756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame plus low glucose maltodextrin
Number of subjects: 44
Study 2756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 44
Study 794003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 794003 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 30
Study 794003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31833000 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMBIA® 50 mg
Number of subjects: 23
Study 31833000 — intervention group
Group type: COMPARATOR
Intervention: IM ketorolac 60 mg
Number of subjects: 23
Study 31653603 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0
Study 31653603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 0
Study 31653603 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study 27918382 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of meropenem (4 hours)
Number of subjects: 102
Study 27918382 — intervention group
Group type: COMPARATOR
Intervention: Conventional infusion of meropenem (30 minutes)
Number of subjects: 102
Study 27918382 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of meropenem
Number of subjects: 102
Study 25432000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrology consult with an interdisciplinary team (nephrologist, social worker, clinical ethicist)
Number of subjects: 0
Study 25432000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional nephrology consult)
Number of subjects: 0
Study 23589556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 3401
Study 23589556 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study 21488053 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF) 6 mg kg(‐1)
Number of subjects: 14
Study 21488053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study 19581850 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg 90 minutes before surgery)
Number of subjects: 52
Study 19581850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16133155 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator concept
Number of subjects: 40
Study 16133155 — intervention group
Group type: COMPARATOR
Intervention: Conventional navigation setup
Number of subjects: 40
Study 16133155 — intervention group
Group type: COMPARATOR
Intervention: Conventional internal and external alignment jigs
Number of subjects: 40
Study 12098150 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid silicone injections (6 injections of 0.2mL)
Number of subjects: 28
Study 12098150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 28
Study 10023509 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 16
Study 10023509 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 7594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group I: 0.3 mg/kg body weight bolus, 0.12 mg/kg per h for 24 h)
Number of subjects: 61
Study 7594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group II: 0.5 mg/kg bolus, 0.24 mg/kg per h for 24 h)
Number of subjects: 61
Study 7594097 — intervention group
Group type: COMPARATOR
Intervention: Heparin (150 IU/kg bolus, 20 IU/kg per h for 24 h)
Number of subjects: 61
Study 7594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group I)
Number of subjects: 61
Study 7594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group II)
Number of subjects: 61
Study 7594097 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 61
Study 2105792 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy with myosin antibody
Number of subjects: 119
Study 2105792 — intervention group
Group type: COMPARATOR
Intervention: 201thallium imaging
Number of subjects: 119
Study 2105792 — intervention group
Group type: COMPARATOR
Intervention: Wall motion assessment at the site of antibody uptake
Number of subjects: 119
Study 6108035 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker)
Number of subjects: 7
Study 6108035 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective drug)
Number of subjects: 7
Study 6108035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6108035 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Propranolol, Metoprolol)
Number of subjects: 7
Study 29982770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in rural South Asia
Number of subjects: 2643
Study 29982770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Sri Lanka
Number of subjects: 2643
Study 29982770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Bangladesh
Number of subjects: 2643
Study 29982770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Pakistan
Number of subjects: 2643
Study 29982770 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with CKD
Number of subjects: 2643
Study 28009680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal focused ultrasound treatment (3 treatments at 2-week intervals)
Number of subjects: 126
Study 28009680 — intervention group
Group type: COMPARATOR
Intervention: Control phase (4-week before treatment)
Number of subjects: 126
Study 28009680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal focused ultrasound treatment
Number of subjects: 126
Study 25671826 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM add-on combination therapy (100 mg LAM and 10 mg ADV per day)
Number of subjects: 136
Study 25671826 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy (0.5 mg ETV per day)
Number of subjects: 136
Study 24069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 69
Study 24069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 69
Study 24069003 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 69
Study 21864353 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Medical Consultations (GMCs)
Number of subjects: 160
Study 21864353 — intervention group
Group type: COMPARATOR
Intervention: Usual care (individual visit)
Number of subjects: 160
Study 19726905 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV prevention education program
Number of subjects: 63
Study 17722824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 30 days
Number of subjects: 54
Study 17722824 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral Gliguidon or subcutaneous insulin)
Number of subjects: 54
Study 17722824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 54
Study 15019802 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of oral DHEA daily for 4 weeks
Number of subjects: 6
Study 11811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Galstena treatment
Number of subjects: 0
Study 9570260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 24
Study 9570260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24
Study 9570260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 125 mg
Number of subjects: 24
Study 9570260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7804673 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 0
Study 7804673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2972306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol given by mouth 12 h before operation
Number of subjects: 86
Study 2972306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30480533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobil‐O‐Graph
Number of subjects: 27
Study 30480533 — intervention group
Group type: COMPARATOR
Intervention: SphygmoCor
Number of subjects: 27
Study 28815789 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine treatment
Number of subjects: 0
Study 28815789 — intervention group
Group type: COMPARATOR
Intervention: Referral to community-based treatment
Number of subjects: 0
Study 28815789 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention and referral
Number of subjects: 0
Study 25203420 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized hyperbolic secant (HS) pulse (μ = 4.25, β = 3040 Hz, A0 = 12.3 μT, Δf = 4598 Hz)
Number of subjects: 6
Study 25203420 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized hyperbolic secant (HS) pulse
Number of subjects: 6
Study 23287079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 139
Study 23287079 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 139
Study 23287079 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol
Number of subjects: 139
Study 21423020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannula placement
Number of subjects: 50
Study 21423020 — intervention group
Group type: COMPARATOR
Intervention: Conventional unguided cannula placement
Number of subjects: 50
Study 18176118 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of erlotinib under fed conditions
Number of subjects: 40
Study 18176118 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of erlotinib under fasting conditions
Number of subjects: 40
Study 18176118 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of erlotinib daily for 8 days under feeding on day 8 after 7 days of fasting
Number of subjects: 40
Study 18176118 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of erlotinib daily for 8 days under fasting on day 8 after 7 days of feeding
Number of subjects: 40
Study 16837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Probio (formula with Lactobacillus johnsonii La1)
Number of subjects: 90
Study 16837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebio (formula with fructo-oligosaccharides)
Number of subjects: 90
Study 16837430 — intervention group
Group type: COMPARATOR
Intervention: Control (infant formula)
Number of subjects: 90
Study 16837430 — intervention group
Group type: EXPERIMENTAL
Intervention: BF (breastfed infants)
Number of subjects: 90
Study 12772236 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent delivery system (Boston Scientific NIR, Guidant Tri‐Star/Tetra, Medtronic AVE S670)
Number of subjects: 256
Study 12772236 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilatation with noncompliant balloons
Number of subjects: 256
Study 12772236 — intervention group
Group type: COMPARATOR
Intervention: Higher deployment pressures (≥ 12 atm)
Number of subjects: 256
Study 10203002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g intravenous dose)
Number of subjects: 13
Study 10203002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 13
Study 8557786 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 99
Study 8557786 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 99
Study 2018901 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution injected at body temperature
Number of subjects: 0
Study 2018901 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic solution injected at room temperature
Number of subjects: 0
Study 6125262 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 6125262 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6
Study 6125262 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 6125262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6
Study 6125262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31750800 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured tetracaine-based anesthetic gel
Number of subjects: 50